A Phase 1/2 interventional study of PiCCO monitoring (PULSION) and central venous catheter in Septic Shock and Acute Respiratory Distress Syndrome, sponsored by Jinhua Central Hospital. Completed at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-05-04.
Sponsored by Jinhua Central Hospital · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Shock, Septic with a site in China — 30 open to participants now, 32 under way, 1 of them phase 3. Shock, Septic · China.
Among the 89 studies in Shock, Septic with a site in China, this one is the 11th largest by enrollment of the 62 interventional ones that give a count, is one of 4 that started in 2012, is one of 4 in phase 1/2, and was the 3rd registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →30 of the 89 studies in Shock, Septic with a site in China are open now. Recruiting first, the newest first:
Nanjing University · Sites in China
Ages 18+ · Healthy volunteers
Sir Run Run Shaw Hospital · Sites in China
Ages 18+ · Healthy volunteers
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18–90
First Affiliated Hospital of Wannan Medical College · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 4 · Phase 4 11
First in 2006; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 350 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 72 across the 62 interventional studies, 148 across the 26 observational. Of the 33 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 89 have an industry lead sponsor. The 10 most frequent:
Jinhua Central Hospital is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Jinhua Central Hospital has 2 studies filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
12 of the studies in Shock, Septic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07367113Ying WangPeripheral Perfusion Index-guided Fluid Resuscitation for Preventing Acute Skin Failure in Elderly Critically Ill Patients | 2026-12 |
| NCT07950943Nanjing UniversityAI Treatment Recommendations With Predicted Consequences for Sepsis Fluid and Vasopressor Decisions | 2026-12-01 |
| NCT07760415Xiangya Hospital of Central South UniversityEEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes | 2026-12-12 |
| NCT06692036Beijing Chao Yang HospitalAdaptive Blood Purification for the Treatment of Patients With Septic Shock | 2026-12-31 |
| NCT06990295First Affiliated Hospital of Wannan Medical CollegeFocused Ultrasound Spleen Stimulation and Inflammation in Septic Shock | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 89 studies in Shock, Septic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PiCCO has been widely used in critical care settings for several decades. Together with pulmonary artery catheter, it is regarded as the important tool for guiding fluid management in patients with shock or acute respiratory distress syndrome. However, its effects on patients' outcome remain untested. The investigators study is a pilot study that is designed to test whether the use of PiCCO will improve patients' outcome, as compared to those without PiCCO monitoring.
PiCCO comprises techniques of pulse contour analysis and transpulmonary thermodilution, and can provide important information on hemodynamics and pulmonary functions. It has been widely used in critical care settings for several decades. Together with pulmonary artery catheter (PAC), it is regarded as the important tool for guiding fluid management in patients with shock or acute respiratory distress syndrome. During last two decades, many well designed clinical trials have been conducted to see whether the use of PAC would benefit patient outcome. The result consistently showed that PAC added no benefit in terms of mortality, ICU length of stay, organ failure free survival days, and the length of mechanical ventilation. Since PiCCO is relatively new to PAC, and its effects on patients' outcome remain untested. The investigators study is a pilot study that is designed to test whether the use of PiCCO will improve patients' outcome, as compared to those without PiCCO monitoring.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients were included if they were diagnosed with Shock, Acute respiratory distress syndrome (ARDS), or both.
Shock was defined by the presence 4 criteria:
Acute respiratory distress syndrome:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients allocated to intervention arm receive PiCCO monitoring for hemodynamics and pulmonary conditions
Device: PiCCO monitoring (PULSION)
Patients in this arm do not receive PiCCO monitoring device to guide fluid management, but central venous catheter can be inserted at the discretion of treating physician.
Procedure: central venous catheter
Patients are monitored with PiCCO system.
Also known as: PiCCO (pulsion medical system, PULSION PiCCO plus)
patients in this arm can receive central venous catheter
30 day mortality
death from any cause before day 30
Time frame: 30 days
14 day mortality
patients were followed up for 14 days
Time frame: 14 days
ICU length of stay
the time from ICU admission to ICU discharge or death
Time frame: up to 30 days
days on mechanical ventilation
days during which the patients are on mechnical ventilation: The criteria for termination of mechanical ventilation: a cooperative patient, recovery from primary disease, hemodynamically stable, adequate and strong cough reflex, positive end-expiratory pressure \<5 cmH2O, pressure support \<10 cmH2O and the spontaneous breathing trial is successfully passed.
Time frame: up to 30 days
days of vasoactive agents support
days during which vasoactive agents are used: The sum of the number of days with one or more vasoactive agents to maintain a mean arterial pressure \>60 mmHg
Time frame: up to 30 days
ICU free survival days during 30-day period
ICU free survival days during 30-day period
Time frame: 30 days
mechanical ventilation free survival days during 30-day period
mechanical ventilation free survival days during 30-day period
Time frame: 28 days
The record gives a start of Jan 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jinhua Central Hospital